| 1 |
Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Kyriakos N, Papaefthymiou A, Giakoumis M, Iatropoulos G, Mantzaris G, Liatsos C. Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. Ann Gastroenterol 2021;34:466-75. [PMID: 34276184 DOI: 10.20524/aog.2021.0635] [Reference Citation Analysis]
|
| 3 |
Xing S, Jiao Y, Salehzadeh M, Soma KK, Huan T. SteroidXtract: Deep Learning-Based Pattern Recognition Enables Comprehensive and Rapid Extraction of Steroid-Like Metabolic Features for Automated Biology-Driven Metabolomics. Anal Chem 2021;93:5735-43. [PMID: 33784068 DOI: 10.1021/acs.analchem.0c04834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 5 |
Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 6 |
Fukuchi T, Koga H, Kaichi S, Ishikawa A, Horita T, Araki R, Yokota A, Namba Y, Kyo M, Eguchi T, Shimazu K. Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis Is Suitable for Elderly Patients With Active Ulcerative Colitis Taking no Corticosteroids or Biologics. Ther Apher Dial. 2019;23:224-232. [PMID: 31025824 DOI: 10.1111/1744-9987.12819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Peterson TE, Siegel CA. Risks and Side Effects of Medical Therapy. Inflammatory Bowel Disease Nursing Manual 2019. [DOI: 10.1007/978-3-319-75022-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 8 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 9 |
Shimazu K, Fukuchi T, Kim I, Noguchi Y, Iwata M, Koyama S, Ubukata S, Tanaka A. Efficacy and Usefulness of New Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis in Active Ulcerative Colitis Patients Without Corticosteroids and Biologics. Ther Apher Dial. 2016;20:383-389. [PMID: 27523079 DOI: 10.1111/1744-9987.12470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 10 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 11 |
Hashiguchi K, Takeshima F, Akazawa Y, Matsushima K, Minami H, Machida H, Yamaguchi N, Shiozawa K, Ohba K, Ohnita K, Ichikawa T, Isomoto H, Nakao K. Advantages of fecal lactoferrin measurement during granulocyte and monocyte adsorptive apheresis therapy in ulcerative colitis. Digestion 2015;91:208-17. [PMID: 25823500 DOI: 10.1159/000375301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 12 |
C. JL. ERRORES FRECUENTES EN EL DIAGNÓSTICO Y TRATAMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. Revista Médica Clínica Las Condes 2015;26:663-666. [DOI: 10.1016/j.rmclc.2015.08.004] [Reference Citation Analysis]
|
| 13 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 14 |
Ott C, Strauch U, Schölmerich J, Kessler H, Hohenberger W. Colitis ulcerosa. Therapie-Handbuch Grundwerk inkl 6. Lfg. 2015. [DOI: 10.1016/b978-3-437-22107-1.50176-x] [Reference Citation Analysis]
|
| 15 |
Osada T, Watanabe S. Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal 2015;61:588-596. [DOI: 10.14789/jmj.61.588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 16 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 17 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 18 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 19 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 20 |
Nakano R, Iwakiri R, Ikeda Y, Kishi T, Tsuruoka N, Shimoda R, Sakata Y, Yamaguchi K, Fujimoto K. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. J Gastroenterol Hepatol 2013;28:303-8. [PMID: 23339387 DOI: 10.1111/jgh.12049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 21 |
Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6:427-433. [PMID: 23170145 DOI: 10.5009/gnl.2012.6.4.427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 22 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 23 |
Yokoyama Y, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, Iimuro M, Yoshida K, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T. The CD4+CD28null and the regulatory CD4+CD25High T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, and following colectomy. Cytokine 2011;56:466-70. [PMID: 21802311 DOI: 10.1016/j.cyto.2011.06.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 24 |
Setoyama H, Ido A, Numata M, Moriuchi A, Yamaji N, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. Life Sci 2011;89:269-75. [PMID: 21763320 DOI: 10.1016/j.lfs.2011.06.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 25 |
Erkrankungen des Dünn- und Dickdarms. Therapie–Handbuch Innere Medizin Sonderedition 2011⁄2012 2011. [DOI: 10.1016/b978-3-437-22702-8.50009-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 26 |
Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther 2011;33:23-32. [PMID: 21083583 DOI: 10.1111/j.1365-2036.2010.04489.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 27 |
Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010;16:2168-72. [PMID: 20848508 DOI: 10.1002/ibd.21305] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 28 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 29 |
Cassina M, Fabris L, Okolicsanyi L, Gervasi MT, Memmo A, Tiboni GM, Di Gianantonio E, Clementi M. Therapy of inflammatory bowel diseases in pregnancy and lactation. Expert Opinion on Drug Safety 2009;8:695-707. [DOI: 10.1517/14740330903357463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 30 |
Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 31 |
Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto T. Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver 2009;3:41-7. [PMID: 20479900 DOI: 10.5009/gnl.2009.3.1.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 32 |
Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600. [PMID: 18679059 DOI: 10.1097/MEG.0b013e3282f5e9f3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 33 |
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. [PMID: 18382085 DOI: 10.1159/000122473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 35 |
Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Antibiotics and probiotics. Falk Symposium. [DOI: 10.1007/978-1-4020-6987-1_17] [Reference Citation Analysis]
|
| 36 |
Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007;26:779-94. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 37 |
Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol 2007;41:677-81. [PMID: 17667052 DOI: 10.1097/MCG.0b013e31802c2a23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 38 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 39 |
Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 40 |
Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M. Antimicrobials in the management of inflammatory bowel disease. Digestion 2006;73 Suppl 1:77-85. [PMID: 16498255 DOI: 10.1159/000089782] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 41 |
Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 2006; 12(21): 3306-3313 [PMID: 16733845 DOI: 10.3748/wjg.v12.i21.3306] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 42 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 43 |
Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 Suppl 1:i36-58. [PMID: 16481630 DOI: 10.1136/gut.2005.081950c] [Cited by in Crossref: 314] [Cited by in F6Publishing: 328] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 44 |
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 45 |
Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005;50:2323-9. [PMID: 16416182 DOI: 10.1007/s10620-005-3055-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 46 |
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Kikuch K, Saniabadi AR. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70:36-44. [PMID: 15297776 DOI: 10.1159/000080079] [Cited by in Crossref: 104] [Cited by in F6Publishing: 111] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 47 |
Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004;20:1347-52. [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 48 |
Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis 2004;10 Suppl 2:S2-10. [PMID: 15475770 DOI: 10.1097/00054725-200407002-00002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 49 |
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-71. [PMID: 15185858 DOI: 10.1023/b:ddas.0000026299.43792.ae] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 50 |
Veljača M. Pharmacotherapy of inflammatory bowel disease: Novel therapeutic approaches. Pharmacotherapy of Gastrointestinal Inflammation 2004. [DOI: 10.1007/978-3-0348-7930-9_2] [Reference Citation Analysis]
|
| 51 |
Steinlauf AF, Chang PK, Traube M. Gastrointestinal Complications. Medical Complications During Pregnancy 2004. [DOI: 10.1016/b978-0-7216-0435-0.50018-3] [Reference Citation Analysis]
|
| 52 |
Thuraisingam A, Leiper K. Medical management of Crohn's disease. Hospital Medicine 2003;64:713-8. [DOI: 10.12968/hosp.2003.64.12.2362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 53 |
Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis 2003;9:205-9. [PMID: 12792229 DOI: 10.1097/00054725-200305000-00011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 54 |
Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40. [PMID: 12105831 DOI: 10.1053/gast.2002.34225] [Cited by in Crossref: 148] [Cited by in F6Publishing: 156] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 55 |
Seegers D, Bouma G, Peña AS. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2002;16 Suppl 4:53-8. [PMID: 12047261 DOI: 10.1046/j.1365-2036.16.s4.8.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 56 |
Cabré E. [Indications for azathioprine treatment in inflammatory bowel disease]. Gastroenterol Hepatol 2002;25:319-26. [PMID: 11985804 DOI: 10.1016/s0210-5705(02)79028-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 57 |
Korelitz BI. Steroids for Crohn's disease--an appreciation and a vote of confidence. Inflamm Bowel Dis 2002;8:219-22. [PMID: 11979144 DOI: 10.1097/00054725-200205000-00010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 58 |
Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97:803-23. [PMID: 12003413 DOI: 10.1111/j.1572-0241.2002.05596.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 59 |
Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-51. [PMID: 11707060 DOI: 10.2165/00003088-200140100-00003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 60 |
Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6. [PMID: 11854604 DOI: 10.1097/00054725-200203000-00002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 61 |
Everts M, Kok RJ, Asgeirsdóttir SA, Melgert BN, Moolenaar TJ, Koning GA, van Luyn MJ, Meijer DK, Molema G. Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. J Immunol 2002;168:883-9. [PMID: 11777986 DOI: 10.4049/jimmunol.168.2.883] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 62 |
Persley K, Scherl E, Rubin P. Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis. Am J Gastroenterol 2001;96:3444-5. [PMID: 11774971 DOI: 10.1111/j.1572-0241.2001.05380.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 63 |
Baldassano RN. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: pro. Why use steroids if safer therapies are available? Inflamm Bowel Dis 2001;7:338-41; discussion 345-6. [PMID: 11720326 DOI: 10.1097/00054725-200111000-00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 64 |
Legnani PE, Kornbluth A. Immunomodulator Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2001;4:199-205. [PMID: 11469977 DOI: 10.1007/s11938-001-0032-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 65 |
Haller C, Markowitz J. A Perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium. Curr Gastroenterol Rep 2001;3:263-71. [DOI: 10.1007/s11894-001-0031-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 66 |
Heuschkel RB. Enteral nutrition in children with Crohn's disease. J Pediatr Gastroenterol Nutr 2000;31:575. [PMID: 11144448 DOI: 10.1097/00005176-200011000-00024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 67 |
&NA;. Avoiding use of corticosteroids in IBD. Inpharma Weekly 2000;&NA;:2. [DOI: 10.2165/00128413-200012300-00002] [Reference Citation Analysis]
|
